The gut-liver axis

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 5, 2013, Pages 576-581

  Visschers, Ruben G J ^a   Luyer, Misha D ^b   Schaap, Frank G ^c   Olde Damink, Steven W M ^c,d   Soeters, Peter B ^c  

^a Sittard Geleen Heerlen   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

autonomous neural system; bile salts; enterohepatic circulation; gut microbiota; metabolic syndrome

Indexed keywords

CHOLECYSTOKININ; FIBROBLAST GROWTH FACTOR 19; LONG CHAIN FATTY ACID;

AUTONOMIC NERVOUS SYSTEM; CHRONIC DISEASE; ENTERITIS; ENTEROHEPATIC CIRCULATION; ENTEROPATHY; HUMAN; INTESTINAL FAILURE; INTESTINE FLORA; LIVER INJURY; NONALCOHOLIC FATTY LIVER; PARENTERAL NUTRITION; REVIEW; VAGUS NERVE;

EID: 84883297669     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32836410a4     Document Type: Review

References (58)

1. Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012; 57:141-149.
2. Menendez JA, Vazquez-Martin A, Ortega FJ, Fernandez-Real JM. Fatty acid synthase: Association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 2009; 55:425-438.
3. Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome: A new worldwide definition. Lancet 2005; 366:1059-1062.
4. Bai Q, Lai X, Zhang AH, et al. Metabolic syndrome and its components associated with endothelial dysfunction in chronic kidney disease patients. Vasc Health Risk Manage 2012; 8:15-21.
5. Tanner R, Brown T, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep 2012; 14:152-159.
6. Sera N, Hida A, Imaizumi M, et al. The association between chronic kidney disease and cardiovascular disease risk factors in atomic bomb survivors. Radiat Res 2013; 179:46-52.
7. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: The critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179:509-516.
8. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. J Invest Dermatol 2012; 132:556-562.
9. Yang CW, Li CI, Liu CS, et al. The joint effect of cigarette smoking and polymorphisms on LRP5, LEPR, near MC4R and SH2B1 genes on metabolic syndrome susceptibility in Taiwan. Mol Biol Rep 2013; 40:525-533.
10. Park SH. Association between alcohol consumption and metabolic syndrome among Korean adults: nondrinker versus lifetime abstainer as a reference group. Substance Use Misuse 2012; 47:442-449.
11. Waterlow JC. Nutritional liver disease in west indian infants. Proc Royal Soc Med 1947; 40:347-351.
12. Kobayashi Y, Niu K, Guan L, et al. Oral health behavior and metabolic syndrome and its components in adults. J Dental Res 2012; 91:479-484.
13. Raphael BP, Duggan C. Prevention and treatment of intestinal failure-associated liver disease in children. Semin Liver Dis 2012; 32:341-347.
14. Angsten G, Finkel Y, Lucas S, et al. Improved outcome in neonatal short bowel syndrome using parenteral fish oil in combination with omega-6/9 lipid emulsions. JPEN J Parenter Enteral Nutr 2012; 36:587-595.
15. Lilja HE, Finkel Y, Paulsson M, Lucas S. Prevention and reversal of intestinal failure-associated liver disease in premature infants with short bowel syndrome using intravenous fish oil in combination with omega-6/9 lipid emulsions. J Pediatr Surg 2011; 46:1361-1367.
16. D?Albuquerque LA, Gonzalez AM, Wahle RC, et al. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl 2008; 14:881-885.
17. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for Kwashiorkor. Science 2013; 339:548-554.
18. Bruinstroop E, la Fleur SE, Ackermans MT, et al. The autonomic nervous system regulates postprandial hepatic lipid metabolism. Am J Physiol Endocrinol Metab 2013; 304:E1089-E1096.
19. Luyer MD, Greve JW, Hadfoune M, et al. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 2005; 202:1023-1029.
20. Lubbers T, De Haan JJ, Hadfoune M, et al. Lipid-enriched enteral nutrition controls the inflammatory response in murine Gram-negative sepsis. Crit Care Med 2010; 38:1996-2002.
21. Luyer MD, Derikx JP, Beyaert R, et al. High-fat nutrition reduces hepatic damage following exposure to bacterial DNA and hemorrhagic shock. J Hepatol 2009; 50:342-350.
22. Lubbers T, de Haan JJ, Luyer MD, et al. Cholecystokinin/Cholecystokinin-1 receptor-mediated peripheral activation of the afferent vagus by enteral nutrients attenuates inflammation in rats. Ann Surg 2010; 252:376-382.
23. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421:384-388.
24. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005; 6:844-851.
25. Rosas-Ballina M, Olofsson PS, Ochani M, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334:98-101.
26. Olofsson PS, Katz DA, Rosas-Ballina M, et al. alpha7 nicotinic acetylcholine receptor (alpha7nAChR) expression in bone marrow-derived non-T cells is required for the inflammatory reflex. Mol Med 2012; 18:539-543.
27. van der Zanden EP, Snoek SA, Heinsbroek SE, et al. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. Gastroenterology 2009; 137:1029-1039.
28. Bockx I, Verdrengh K, Vander Elst I, et al. High-frequency vagus nerve stimulation improves portal hypertension in cirrhotic rats. Gut 2012; 61:604-612.
29. Nehra D, Fallon EM, Puder M. The prevention and treatment of intestinal failure-associated liver disease in neonates and children. Surg Clin North Am 2011; 91:543-563.
30. Kurvinen A, Nissinen MJ, Andersson S, et al. Parenteral plant sterols and intestinal failure-associated liver disease in neonates. J Pediatr Gastroenterol Nutr 2012; 54:803-811.
31. Naini BV, Lassman CR. Total parenteral nutrition therapy and liver injury: A histopathologic study with clinical correlation. Hum Pathol 2012; 43:826-833.
32. Xu Z, Li Y, Wang J, et al. Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. Clin Nutr 2012; 31:217-223.
33. Reniers D, Rajakumar I, Ratko S, Atkison P. Use of parenteral fish oil to reverse cholestasis induced by parenteral nutrition in infants with intestinal failure: Single-centre case series. Can J Hosp Pharm 2012; 65:27-30.
34. Klek S, Chambrier C, Singer P, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid) -A double-blind, randomised, multicentre study in adults. Clin Nutr 2013; 32:224-231.
35. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284:1362-1365.
36. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284:1365-1368.
37. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89:147-191.
38. Modica S, Petruzzelli M, Bellafante E, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142:355-365.
39. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49:1228-1235.
40. Nijmeijer RM, Gadaleta RM, van Mil SW, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011; 6:e23745.
41. Lichtenstein DR. Hepatobiliary complications of inflammatory bowel disease. Curr Gastroenterol Rep 2011; 13:495-505.
42. van Schaik FD, Gadaleta RM, Schaap FG, et al. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis. PLoS One 2011; 7:e49706.
43. Sayin SI, Wahlstro?m A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17:225-235.
44. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101:15718-15723.
45. Sommer F, Backhed F. The gut microbiota: Masters of host development and physiology. Nat Rev Microbiol 2013; 11:227-238.
46. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: Their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013; 56:461-468.
47. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575-1584.
48. Cryan JF, Dinan TG. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nature reviews. Neuroscience 2012; 13:701-712.
49. Kim JY, Park MS, Ji GE. Probiotic modulation of dendritic cells co-cultured with intestinal epithelial cells. World J Gastroenterol 2012; 18:1308-1318.
50. McLoughlin RM, Mills KH. Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. J Allergy Clin Immunol 2011; 127:1097-1107.
51. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83:1010-1016.
52. Wolfs TG, Derikx JP, Hodin CM, et al. Localization of the lipopolysaccharide recognition complex in the human healthy and inflamed premature and adult gut. Inflamm Bowel Dis 2010; 16:68-75.
53. Hodin CM, Visschers RG, Rensen SS, et al. Total parenteral nutrition induces a shift in the Firmicutes to Bacteroidetes ratio in association with Paneth cell activation in rats. J Nutr 2012; 142:2141-2147.
54. Mouzaki M, Comelli E, Arendt B, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; PMID: 23401313 or doi:10.1002/hep.26319.
55. Million M, Lagier JC, Yahav D, Paul M. Gut bacterial microbiota and obesity. Clin Microbiol Infect 2013; 19:305-313.
56. El Kasmi KC, Anderson AL, Devereaux MW, et al. Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury. Hepatology 2012; 55:1518-1528.
57. Liu J, Wu D, Ahmed A, et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr Microbiol 2012; 65:7-13.
58. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013; 57:601-609.